Insulin-Like Growth Factor-1 as a Prognostic Marker in Patients with Acute Ischemic Stroke

Tang, Jianhua; Ma, Lili; Yu, Tianxia; Zheng, Juan; Zhang, Huijuan; Liang, Hui; Shao, Pengfei

doi:10.1371/journal.pone.0099186

Cited by 33 publications

(41 citation statements)

References 34 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Extensive numbers of clinical studies have shown that lower IGF-1 levels significantly increase the risk of stroke and higher IGF-1 levels are associated with improved stroke outcomes, suggesting the circulating IGF-1 level may be used as a predictive value for ischemic stroke outcome (De Smedt et al 2011; Dong et al 2014; Tang et al 2014) and post-stroke IGF-1 treatment may be beneficial to both sexes. However, a recent study using miRNA that regulate IGF-1 found sex differences in the efficacy of this treatment.…”

Section: Sex Differences In Treatment Efficacy In Preclinical Studiesmentioning

confidence: 99%

“…It has been well established clinically that serum IGF-1 levels are positively correlated with stroke outcome. Many clinical studies have shown that lower IGF-1 levels significantly increase the risk of stroke and that higher IGF-1 levels are associated with improved stroke outcomes, suggesting that the circulating IGF-1 level may be used as a predictive value for ischemic stroke outcome (De Smedt et al, 2011;Dong et al, 2014;Tang et al, 2014) and that poststroke IGF-1 treatment may be beneficial for both sexes. However, using miRNA that regulate IGF-1, Selvamani and colleagues (2012) showed sex differences in the efficacy of this treatment and showed that intracerebroventricular anti-Let7f injection is effective only in intact females and not in males or ovariectomized females, suggesting that this miRNA action may be influenced by the hormonal milieu (Selvamani et al, 2012).…”

Section: Cell Survival Effector: Insulin-like Growth Factor-1mentioning

confidence: 99%

See 1 more Smart Citation

Sex differences in stroke therapies

Sohrabji

Park

Mahnke

2016

J of Neuroscience Research

View full text Add to dashboard Cite

Stroke is the 5th leading cause of death and acquired disability in aged populations. Women are disproportionally affected by stroke, having a higher incidence and worse outcomes than men. Numerous preclinical studies have discovered novel therapies for the treatment of stroke, but almost all of these were found to be unsuccessful in clinical trials. Despite known sex differences in occurrence and severity of stroke, few therapeutics, both preclinically and clinically, take into account possible sex differences in treatment. Reanalysis of data from the only currently FDA-approved stroke therapy, tPA, has shown to not only improve stroke outcomes for both sexes, but to also show sexual dimorphism by more robust improvement in stroke outcome in females. Experimental evidence supports the inclusion of sex as a variable in the study of a number of novel stroke drugs and therapies, including preclinical studies of anti-inflammatory drugs (minocycline), stimulators of cell survival (IGF-1), and inhibitors of cell death pathways (pharmacological inhibition of PARP-1, NO production, and caspase activation), as well as in current clinical trials of stem cell therapy and cortical stimulation. Overall, study design and analyses in clinical trials, as well as in preclinical studies, must include both sexes equally, consider possible sex differences in the analyses, and report the differences/similarities in more systemized/structured way to translate promising therapies to both sexes and increase stroke recovery.

show abstract

Section: Sex Differences In Treatment Efficacy In Preclinical Studiesmentioning

confidence: 99%

Section: Cell Survival Effector: Insulin-like Growth Factor-1mentioning

confidence: 99%

Sex differences in stroke therapies

Sohrabji

Park

Mahnke

2016

J of Neuroscience Research

View full text Add to dashboard Cite

show abstract

“…[3][4][5] Previous studies regarding stroke patients have suggested that low IGF-1 levels in the circulation are related with higher stroke severity, poor outcome, and less rates of survival after stroke. [6][7][8][9] De Smedt et al (2011) suggested that high serum IGF-I levels after the onset of ischemic stroke are associated with neurological recovery and a better functional outcome.…”

Section: Introductionmentioning

confidence: 99%

The relation between insulin‐like growth factor 1 levels and risk of depression in ischemic stroke

Zhang

Wang

Kuang

2017

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…Higher levels of IGF-1 with simultaneously low levels of IGFBP-3 allow for greater amounts of free, unbound IGF-1 in circulation, which, in turn, elicits IGF-1 to trigger cascades in neuroprotective pathways. In individuals with stroke, many studies have agreed that high baseline levels of IGF-1 in circulation, measured once within the first few weeks of stroke, are linked to lower stroke severity and greater rates of survival at one-month post stroke (6–11). …”

Section: Introductionmentioning

confidence: 99%

Decrease in Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor-1 Ratio in the First Week of Stroke Is Related to Positive Outcomes

Mattlage

Rippee

Sandt

et al. 2016

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

Background High insulin-like growth factor-1 (IGF-1), measured once during acute-stroke, is associated with greater survival rates and lower stroke severity. However, information is lacking regarding how IGF-1 availability, determined by IGF-1’s ratio to insulin-like growth factor binding protein-3 (IGFBP-3), relates to recovery and how the response of IGF-1 during the first week of stroke relates to outcomes. The purpose of this study was to determine: 1) the relationship between percent-change in IGF-1 and IGF-1 ratio during the first week of stroke and stroke outcomes; and 2) the difference in percent-change in IGF-1 and IGF-1 ratio in individuals who discharged home and individuals who discharged to inpatient facilities. Methods IGF-1 and IGFBP-3 were quantified from blood sampled twice (<72 hours of admission; 1-week post-stroke) in fifteen individuals with acute-stroke. Length of stay, modified Rankin Scale at one-month, and discharge destination were obtained from electronic medical records. Results Percent-change in IGF-1 ratio was related to length of stay (r=.54; p=.04). Modified Rankin Scale (n=10) was related to percent-change in IGF-1 (r=.90; p<.001) and IGF-1 ratio (r=.75 p=.01). Those who went home (n=7) had decreases in IGF-1 (−24±25%) and IGF-1 ratio (−36±50%), while those who went to inpatient facilities (n=8) had increases in IGF-1 (37±46%) and IGF-1 ratio (30±40%). These differences were significant (IGF-1: p=.008; IGF-1 ratio p=.01). Conclusion Our findings suggest that a decrease in IGF-1 and IGF-1 ratio during the first week of stroke is associated with favorable outcomes: shorter length of stay, greater independence at one-month on the modified Rankin Scale, and discharging home.

show abstract

Insulin-Like Growth Factor-1 as a Prognostic Marker in Patients with Acute Ischemic Stroke

Cited by 33 publications

References 34 publications

Sex differences in stroke therapies

Sex differences in stroke therapies

The relation between insulin‐like growth factor 1 levels and risk of depression in ischemic stroke

Decrease in Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor-1 Ratio in the First Week of Stroke Is Related to Positive Outcomes

Contact Info

Product

Resources

About